Stockscreener 앱 받기
1.92
5.88%
-0.12
시장 영업 전:
1.90
-0.02
-1.04%
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest
Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire
Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan
Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times
Revolutionary Female Viagra Cream DARE to PLAY Gets Major Launch Campaign Before Q4 Release - Stock Titan
Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks
Daré Bioscience Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - Autocar Professional
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties - TipRanks
Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada
Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize
3 Penny Stocks to Watch Now, 7/15/25 - TipRanks
Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia
US Stocks End Higher Amid Tariff Concerns: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Greed' Zone - Benzinga
Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest
Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks
Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene - TipRanks
Daré Bioscience stock soars after positive interim Phase 3 contraceptive results - Investing.com India
Daré Bioscience Soars 250% on Positive Ovaprene Trial Data - Wall Street Pit
Dare Bioscience’s Unforeseen Stock Skyward Leap - StocksToTrade
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - Benzinga
Dare Bioscience Reflects on Grant Milestone - timothysykes.com
Daré Bioscience reports positive interim results for hormone-free contraceptive By Investing.com - Investing.com South Africa
Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks
Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge - MarketScreener
Daré Bioscience Announces Positive Phase 3 Trial Results - TipRanks
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - The Manila Times
Daré Bioscience Announces Positive Interim Results from Phase 3 Trial of Hormone-Free Contraceptive Ovaprene® - Quiver Quantitative
Dare Bioscience Plunges 11.33% Amid Market Shifts - AInvest
Daré Bioscience receives $6 million installment for contraceptive device - Investing.com Australia
Daré Bioscience Receives $6 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience Sees Stock Surge Amid Strategic Collaborations - StocksToTrade
Daré Bioscience receives $6 million installment for contraceptive device By Investing.com - Investing.com South Africa
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewswire
Daré's Smart Drug Delivery Platform Secures $6M Grant, Eyes Expansion into $B Obesity Market - Stock Titan
Dare Bioscience shareholders approve board nominees and stock plan amendment - Investing.com Nigeria
Daré Bioscience Stockholder Meeting Approves Key Proposals - TipRanks
Daré Bioscience Gains Nasdaq Compliance Extension Approval - TipRanks
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders | DARE Stock News - GuruFocus
0.24%
3.39%
자본화:
|
볼륨(24시간):